CSL to pay $450M to buy uniQure's hemophilia B gene therapy Sangamo R&D chief hits the exit as it splits R&D into separate units Bristol Myers says Celgene buyout could supercharge sales to $20B Sponsored: Rise in Targeted Therapies Drives Need for Flexible Small-Volume Manufacturing Relay Therapeutics tees up $200M IPO to push a trio of oncology meds Sosei pens inflammatory and autoimmune disease drug pact with AbbVie Regeneron identifies new combos to boost I-O drug Libtayo's cancer response U.K. launches new national COVID-19 test validation project Featured Story | Thursday, June 25, 2020 CSL Behring has struck a deal to buy uniQure’s late-phase hemophilia B gene therapy AMT-061 for $450 million upfront. The agreement will catapult CSL to the front of the race to bring a hemophilia B gene therapy to market, pitting it against companies including Pfizer. read more |
| |
|---|
|
Top Stories Wednesday, June 24, 2020 A week after presenting updated data from its Pfizer-partnered bleeding disorder gene therapy, Sangamo is making some big changes to its R&D. read more Thursday, June 25, 2020 Bristol Myers Squibb upped its forecast of annual sales from its late-stage pipeline from $15 billion to $20 billion, starting in the second half of the decade. Those sales will be led by products picked up in its $74 billion Celgene buyout. read more Monday, June 22, 2020 Innovative therapies target small numbers of patients. Smaller demand for a therapy, means that sterile injectable manufacturing needs to accommodate smaller batch sizes and more flexibility. read more Wednesday, June 24, 2020 A year and a half after banking $400 million in its series C round, Relay Therapeutics is ready to go public. The company filed to raise up to $200 million in its Nasdaq IPO, which will move two oncology programs into midphase development and push a third toward the clinic. read more Thursday, June 25, 2020 Sosei Heptares saw its shares shoot up around 12% in Tokyo this morning on news it has signed a new pact with AbbVie. read more Wednesday, June 24, 2020 Looking for ways to improve responses to PD-1 inhibitors in cancer, scientists at Regeneron turned to bispecific antibodies that bridge T cells and tumor cells. A new study showed that a combination of bispecific antibodies targeting CD28 with Regeneron's PD-1 inhibitor Libtayo led to enhanced anti-tumor activity in multiple mouse models. read more Wednesday, June 24, 2020 The U.K. government is launching a national research program, in collaboration with a number of universities, NHS trusts and medical research groups, to evaluate new coronavirus diagnostic tests and how well they perform in different settings. read more Enrollment Showcase | Sponsored by: University of Florida College of Pharmacy University of Florida precision medicine leaders highlight current knowledge and trends to advance the future of health care in this quarterly webinar series. Register today. |
| |
|---|
|
Resources Sponsored by: Systech Get an inside look… Merck shares its next-generation approach to supply chain protection with new digital platforms, including Blockchain. Presented by: Cytiva On-demand video: fuel gene therapy development and production with modern AAV workflows. Sponsored by: Automation Anywhere Built on advances in Artificial Intelligence (AI), data mining, and information integration into various systems at 100% accuracy, the new era of intelligent automation is integral to life sciences for devising new treatments faster and at a lower expense. Sponsored by: Cenduit Download this case study to read how Cenduit helped one client successfully navigate mid-study changes to medication management. Sponsored by: Research Solutions Learn four ways to squeeze more value from your limited R&D resources. Sponsored by: BioAnalytix Download this eBook and Learn the Advanced Analytical Approaches for Improved Development of Cell and Gene Therapies Sponsored by: Catalent In a series of innovation sessions, Catalent RP Scherer softgel capsules were quickly identified as the ideal solution to drive incremental growth. Learn more. Sponsored by: Blue Matter, strategic consultants in the life sciences White paper describing 7 keys to success for any biopharma company that is entering (or thinking about entering) Europe. Sponsored by: Clinical Ink This white paper covers a Phase III case study; BYOD advantages and misconceptions; and regulatory, copyright, and equivalency considerations. Sponsored by: Clinical Ink Learn how GI specific data capture solutions can support virtual and hybrid trials during COVID-19. Sponsored by: Copyright Clearance Center Dive into the history of biomedical classification and how these systems have evolved to address new technology and use cases. Presented by: ICON Clinical Research Download this whitepaper to learn more about the success factors that are required to keep a pandemic respiratory vaccine trial running at optimal speed and efficiency. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Wednesday, May 20, 2020 | Time: 10am-3.30pm (BST) Join us for a day of discovery as global experts in Cardiology, Pharmacology and Diabetes discuss state of the art methods in early phase clinical research. Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now. | COVID19 provisions – training will be on-site as normal. | New – may be possible for some individuals to access the training virtually in real time. | 